Transcription profiling by array of Lipocalin 2 expression in endometrial cancer

Submitted Feb. 23, 2012 ·Released April 1, 2012 ·Updated May 3, 2014

Samples

Assays

Array Platforms

References

Description

The aim of the present study was to investigate LCN2 in endometrial cancer in relation to clinico-pathologic phenotype, angiogenesis, markers of epithelial-mesenchymal transition (EMT), and patient survival.

References

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB.

PMID: 23099803

Lipocalin 2 expression is associated with aggressive features of endometrial cancer.

Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Oyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA.

PMID: 22559235

Array Platforms

A-AGIL-28

Agilent Whole Human Genome Microarray 4x44K 014850 G4112F (85 cols x 532 rows)（76 items）

Sample Attributes

ClinicalInformation

primary tumor

DiseaseState

endometrial cancer

Organism

Homo sapiens

Experiment Info

Accession

E-MTAB-1007

Type

transcription profiling by array

Organism

Homo sapiens

Submitted

Feb. 23, 2012

Released

April 1, 2012

Updated

May 3, 2014

Submitter

Marsha A Moses、 Lars A Akslen、 Maria B Raeder、 Anne M Ãyan、 Ingunn M Stefansson、 Kjell Petersen、 Monica Mannelqvist、 Karl-Henning Kalland、 Helga B Salvesen、 Elisabeth Wik

External Links

ArrayExpress source

Analysis Services

Transcription profiling by array of Lipocalin 2 expression in endometrial cancer

Contact

WeChat Official Account